Organic Active Ingredients TRIZ Cases

A two-stage intravitreal injector releases lubricious material before the drug to lower injection force, avoid air trapping, and improve dosing.

Fluorinated pyridine-based CaMKII inhibitors improve cardiovascular treatment while reducing cytotoxicity and off-target kinase effects.

Selective Cbl-b inhibitor compounds enhance immune cell activity while addressing off-target risk in cancer-focused immunomodulation.

Using R(-)-ketamine without S(+)-ketamine preserves antidepressant effect while lowering side effects and abuse risk for use outside clinics.

A lyophilized injectable formulation uses solubilizing, hydrotropic, and pH-modifying agents to improve solubility and long-term stability.

Adsorbing low-dose corticosteroids onto silicified microcrystalline cellulose improves ODT uniformity and topical esophageal treatment with fewer systemic effects.

Virtual screening repurposes approved drugs that bind SARS-CoV-2 Mpro or RdRP, improving antiviral effect while limiting side effects.

Controlled ondansetron particles in a viscous injectable suspension deliver uniform release for 2 to 10 days while reducing repeat dosing and site irritation.

Chemical modification of cannabidiol improves oral absorption and half-life while reducing toxicity and side effects in therapeutic use.

Selective MK2 inhibitors bind the MK2 C-terminal domain to block the p38/MK2 axis, reduce cytokine production, and improve safety.

Deuterated chromene combinations reduce PGE2 while boosting checkpoint-driven immune response for safer cancer treatment.

Selective rapamycin analogs tune mTORC1 or mTORC2 inhibition to avoid unwanted Akt blockage while improving mTOR-driven disease treatment.

Selective aza-quinoline compounds target EZH2 catalytic activity to inhibit PRC2-driven disease pathways while limiting off-target effects.

Urea and lactic acid formulations help short therapeutic oligonucleotides cross the stratum corneum and reach the dermis for gene silencing.

Protein and nucleic acid factors reduce ROS and boost cell growth to enable less invasive cellular rejuvenation and tissue regeneration.

Dimethoxyphenyl piperazine compounds cap alpha-synuclein fibril ends, while a rapid FlAsH assay detects inhibitor effects in 3 hours.

Isoform-selective PI3Kα inhibition improves tumor suppression while reducing diarrhea, rash, fatigue, and hyperglycemia from pan-PI3K activity.

Topical lopinavir alone or with ritonavir suppresses HSV replication, including acyclovir-resistant strains, with lower host-cell toxicity.

Modified vincamine lipids improve blood-brain barrier transport and lysosomal escape for nucleic acid drugs while lowering toxicity risks.

Novel compound structures target PKC-theta with strong inhibition and improved isoform selectivity for autoimmune, inflammatory, and cancer therapy.

Dual-acting acylated glucagon analogues target glucagon and GLP-1 receptors to reduce food intake and improve glucose control.

Quercetin-mediated zinc influx and TWIK2 inhibition help an immune drink composition reduce inflammation and support immune function.

Generative AI explores chemical space to create PI3K-alpha inhibitors with higher selectivity, fewer off-target effects, and better resistance control.

Anti-PODXL neutralizing antibodies disrupt circulating tumor cell clusters, reduce metastasis, and improve chemotherapy sensitivity.

A polymer-matrix oral film paired with PION testing captures rapid dissolution at fine time intervals for consistent drug delivery.

Twice- or thrice-daily controlled-release levodopa combines immediate and modified release to stabilize plasma levels and reduce Parkinson's motor fluctuations.

TOFA and related analogs target glucose, insulin, obesity, and liver disease progression in metabolic disorders linked to NAFLD and NASH.

A biochemical presbyopia treatment reduces lens stiffness through disulfide reduction and AGE inhibition for longer-lasting accommodation.

Novel heterocyclic compounds inhibit sPLA2-X to address relapse and refractory disease in cancer treatment and related conditions.

Chiral amine or enzyme resolution enables preparation of high-purity (R)-ketorolac with improved yield where prior routes lacked access to this isomer.

A joint-penetrating hyaluronic acid hydrogel crosslinks in situ to extend residence time, reinforce cartilage, reduce fibrosis, and support repair.

Novel ROCK1 and ROCK2 inhibitor compounds improve isoform selectivity, solubility, and pharmacokinetics while reducing cytotoxicity.

Single-chain nanoparticles keep drug carriers under 20 nm for stronger tumor accumulation, longer blood retention, and lower off-target effects.

A water- and ethanol-free glycerin vehicle keeps amlodipine stable, lowers impurities, and delivers uniform oral dosing without suspension limits.

Double-stranded RNA targets INHBE mRNA for degradation, improving gene silencing specificity while managing sequence design complexity.

A natural Conessine composition addresses the safety-efficacy tradeoff in influenza A treatment by strongly inhibiting IAV with low cellular toxicity.

A cured high-molecular-weight PEO matrix enables oral ketamine extended release, reducing dissociative effects and dosing frequency.

Specific amino acid ratios modulate IL-6 to curb skin inflammation while preserving immune response and supporting collagen and elastin synthesis.

New crystalline lumateperone salts use tailored benzenesulfonate counterions to improve stability and low solubility for sustained-release injectables.

A gamma/beta-cyclodextrin copolymer improves cholesterol efflux while limiting membrane cholesterol extraction, cytotoxicity, and hemolysis.

Targeted C-17 and 19-alkoxy steroid changes improve GABAA anesthetic activity while supporting solubility and lower contamination risk.

Bridged tricyclic carbamoylpyridones improve metabolic stability and drug exposure to limit resistance, toxicity, and frequent HIV dosing.

Highly selective antibodies block latent myostatin activation without affecting GDF11, supporting muscle growth with lower toxicity risk.

A multi-ingredient pet supplement uses resistant starch, beta glucan, probiotics, L-carnitine, and alpha lipoic acid to support weight loss and gut health.

Allogeneic Vδ1+ γδ T cells bypass MHC restriction to kill chemoresistant AML blasts, home to bone marrow, and persist after treatment.

By recruiting BTK to cereblon for ubiquitin-driven degradation, these bifunctional compounds overcome C481S-linked resistance and block BCR signaling.

A thiazole compound restores ER homeostasis to prevent melanocyte death and improve pigmentation in vitiligo and related skin autoimmune disorders.

Dual FAK and RAF/MEK inhibition addresses weak RAS-mutant cancer control by reducing tumor growth and improving immune response.

Intermittent allopregnanolone dosing activates endogenous neural stem cells to restore cognition and reduce Alzheimer's pathology.

Combined ocular gene delivery and steroid treatment targets VEGF-driven retinal disease while limiting intraocular inflammation.